TGFB1 and chronic kidney disease: Shenkang injection exhibits anti-fibrotic and renal protective effects in in vivo and in vitro animal models and cell experiments by inhibiting the TGF-β/Smad3 signaling pathway, regulating mitochondrial autophagy, reducing oxidative stress and inflammatory responses, providing potential molecular mechanisms and clinical application prospects for the treatment of CKD (57–59).